Clinical trial • Phase III • Oncology

Clinical trial in Glioma | Glioblastoma multiforme

Phase III trial for Glioma | Glioblastoma multiforme. 18 participants.

Overview

Trial Therapeutic Area
Oncology
Trial Disease
Glioma | Glioblastoma multiforme
Trial Stage
Phase III

Key dates

Initial CTIS Submission Date
26-09-2025
First CTIS Authorization Date
09-12-2025

Trial design

Phase III trial across 1 site in Netherlands.

Target Sample Size
18

Eligibility

Recruits 18 Vulnerable population selected; no details on consent or assent handling provided..

Vulnerable Population
Vulnerable population selected; no details on consent or assent handling provided.

Recruitment

Planned Sample Size
18
Recruitment Window Months
6

Geography

Total Number Of Sites
1
Total Number Of Participants
18

Netherlands

Earliest CTIS Part Ii Submission Date
22-11-2025
Latest Decision Or Authorization Date
09-12-2025
Processing Time Days
17
Number Of Sites
1
Number Of Participants
18

Sites

Site Name
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Department Name
Neurosurgery
Principal Investigator Name
Clemens Dirven
Principal Investigator Email
c.dirven@erasmusmc.nl
Contact Person Name
Clemens Dirven
Contact Person Email
c.dirven@erasmusmc.nl
Number Of Participants
18

Sponsor

Primary sponsor

Full Name
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Organisation Type
Hospital/Clinic/Other health care facility
Country Of Registered Address
Netherlands

Related trials

Other published trials that may interest you.